Bernards Rene 4
4 · LIXTE BIOTECHNOLOGY HOLDINGS, INC. · Filed Jan 22, 2025
Insider Transaction Report
Form 4
Bernards Rene
Director
Transactions
- Award
Options to Purchase Common Stock
2025-01-20+4,166→ 4,166 totalExercise: $2.33From: 2025-01-20Exp: 2030-01-20→ Common (4,166 underlying)
Holdings
- 5,304
Options to Purchase Common Stock
Exercise: $1.30From: 2024-09-30Exp: 2029-09-30→ Common (5,304 underlying) - 10,000
Options to Purchase Common Stock
Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (10,000 underlying) - 4,149
Options to Purchase Common Stock
Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (4,149 underlying)
Footnotes (1)
- [F1]Effective January 20, 2025, the reporting person was granted stock options to purchase an aggregate of 4,166 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.